Organisation paid for research Program year 2025 Source: CMS Open Payments

Pharmaceutical Research Consulting Inc

Neither a doctor nor a teaching hospital

Research payments

$130,359

34 payments

Through program year 2025, Pharmaceutical Research Consulting Inc is reported as receiving $130,359 in research payments, across 34 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$84,460	13
2022	Research	$2,145	2
2021	Research	$21,529	4
2020	Research	$20,894	12
2019	Research	$1,331	3

Breakdown

Who paid Research payments · program years 2019–2025

Sanofi US Services Inc. $130,359 34 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) $84,460 13 payments
A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP) $23,674 6 payments
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients na $12,549 3 payments
Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naive to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab $6,095 6 payments
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial $2,250 3 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 $926 2 payments
Open Label Extension study to evaluate the long term safety and tolerability of Dupilumab in patients with asthma who participated in previous dupilumab asthma clinical study $405 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.